Staphylococcus aureus is recognized as commensal as well as opportunistic pathogen of
humans and animals. Methicillin resistant strain of S. aureus (MRSA) has emerged as a …

Daptomycin (DAP) is a cyclic lipopeptide with in vitro activity against a variety of Gram‐
positive pathogens, including multidrug‐resistant organisms. Since its introduction into …

This review is the result of discussions that took place at the 5th MRSA Working Group
Consensus Meeting and explores the possible treatment options available for different types …

Background Daptomycin and ceftaroline (DAP-CPT) have been used for persistent
methicillin-resistant Staphylococcus aureus bacteremia (MRSAB), but have rarely been …

Outcomes from methicillin-resistant Staphylococcus aureus (MRSA) infections are relatively
poor, at least in part due to the limitations of vancomycin (the current standard treatment for …

Objectives Dalbavancin is a long-acting lipoglycopeptide with activity against gram-
positives, including methicillin-resistant Staphylococcus aureus (MRSA). The potential for …

There has been a welcome increase in the number of agents available for the treatment of
methicillin-resistant Staphylococcus aureus (MRSA). Vancomycin remains an acceptable …

The high prevalence of methicillin resistance among Staphylococcus aureus bacteremias
leads to common use of vancomycin as empirical therapy. However, investigators have …

Methicillin-resistant Staphylococcus aureus (MRSA) continues to be a major public health
problem. Vancomycin and teicoplanin have been in clinical use for several decades but their …

Complicated methicillin-resistant Staphylococcus aureus bloodstream infections (MRSA-
BSIs), particularly those with delayed culture clearance, are associated with high mortality …